Login to Your Account

Clinic Roundup

Friday, July 20, 2012
• Conatus Pharmaceuticals Inc., of San Diego, and the University of Alberta said they treated the first patient in an islet cell transplant Phase I/II trial testing emricasan (IDN-6556), a pan-caspase inhibitor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription